CavaliereCFratiFRidoloE, et al. The spectrum of therapeutic activity of mepolizumab. Expert Rev Clin Immunol. 2019;15(9):959-967.
2.
LinSLuoDGongZZhanQ.Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database. Front Med. 2024;11:1449194.
3.
PhillippsJBhasinASluzevichJ.Exploring mepolizumab use in chronic spontaneous urticaria: an open-label, single-arm, exploratory study. J Allergy Clin Immunol Pract. 2025;13(9):2503-2505.e1. doi:10.1016/j.jaip.2025.06.014
4.
KangEGNarayanaPKPouliquenIJLopezMCFerreira-CornwellMCGetsyJA.Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis. Allergy. 2020;75(4):950-953.
5.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
